Sutro Biopharma Inc. is ready for war.
The South San Francisco biotech company closed the second tranche of a $36 million Series C venture round, it said Tuesday, and is readying the infrastructure it needs to produce highly targeted, cancer-fighting antibody-drug conjugates.
No comments:
Post a Comment